Sign In
Buy BAYRY
$9.92
+0.0400 (+0.405%)
At Close: Jun 03, 2026
Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug
10:45am, Friday, 23'rd Aug 2024
Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.
Appeals Court Rules in Favor of Bayer-Owned Monsanto in Roundup Cancer Case
10:55am, Friday, 16'th Aug 2024
In a big victory for Bayer-owned Monsanto, a federal court overturned a verdict finding the company responsible over claims its Roundup weed killer causes cancer.
Bayer wins big US legal victory against Roundup cancer claims; shares surge
10:01am, Friday, 16'th Aug 2024
Bayer won a big legal victory in its fight to limit liability from claims its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law shields the German company from a
Bayer shares surge 10% after major legal victory in Roundup cancer litigation: Time to buy?
08:34am, Friday, 16'th Aug 2024
Bayer AG saw its shares soar by 10% in early German trading following a crucial legal victory concerning its Roundup weedkiller. The surge came after a Philadelphia appeals court ruled in favor of Bay
Bayer's stock surges after U.S. appeals court strikes down Roundup cancer case
07:51am, Friday, 16'th Aug 2024
Bayer AG shares surged up to 12% Friday on news it had won a key victory in a U.S. court that should limit its liability in relation to a series of lawsuits over claims that the popular weed killer Ro
Bayer shares soar 12% after key U.S. legal win against Roundup cancer claims
06:45am, Friday, 16'th Aug 2024
Bayer shares rose as the company said it scored a legal victory in its suit over claims that exposure to its popular Roundup weed killer led to cancer.
Bayer wins victory in US legal battle against Roundup cancer claims
02:48pm, Thursday, 15'th Aug 2024
Bayer won a legal victory in its fight to limit liability from claims that its Roundup weed killer causes cancer, as a U.S. appeals court on Thursday said federal law shields the German company from a
Bayer: Risks Remain While Business Is Stabilizing
05:00pm, Thursday, 08'th Aug 2024
Bayer reported second quarter results and while the results were nothing to get excited about, it was at least not a disappointment. While the Crop Sciences segment is still struggling, Pharmaceutical
Bayer: Why I'm Careful, But Rate It Buy
12:56pm, Tuesday, 06'th Aug 2024
I recommend keeping a close eye on Bayer's performance and potential investment opportunities. I have been cautious about Bayer since last article, which discussed the company cutting its dividend. Ba
Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales
10:20am, Tuesday, 06'th Aug 2024
Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.
Bayer's Monsanto to pay $160 mln to resolve Seattle's PCB contamination lawsuit
02:53pm, Thursday, 25'th Jul 2024
Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer of polluting the city's drainage system and the local Lower Duwamish River with toxic
Australian judge dismisses lawsuit claiming Bayer's Roundup weedkiller causes cancer
01:49am, Thursday, 25'th Jul 2024
An Australian judge said on Thursday it was not proven that an ingredient in Bayer's Roundup weedkiller increases the risk of cancer in users.
Australian court to rule on whether Bayer weedkiller can cause blood cancer
12:02am, Thursday, 25'th Jul 2024
An Australian judge will rule on Thursday on whether Bayer's Roundup weedkiller can cause a type of blood cancer, a closely watched decision that follows some jury verdicts in similar U.S. cases that
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
10:11am, Thursday, 18'th Jul 2024
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
Bayer says darolutamide shown to slow prostate cancer progression
01:43am, Wednesday, 17'th Jul 2024
Bayer said on Wednesday its drug candidate darolutamide was shown to slow the progression of certain types of prostate cancer in a late-stage trial.
